| OCUGEN INC. DL-,001 |
| USA |
| Gesundheit |
| US67577C1053 / A2PSZH |
| 2H51 (Frankfurt) / OCGN (NASDAQ) |
| FRA:2H51, ETR:2H51, 2H51:GR, NASDAQ:OCGN |
| - |
| https://ocugen.com/ |
|
Ocugen Inc. is a biopharmaceutical company headquartered in Malvern, Pennsylvania, specializing in the discovery, development, and commercialization of gene therapies, cell therapies, and vaccines. The company's primary focus centers on rare inherite..
>Volltext.. |
| 508.47 Mio. EUR |
| 520.87 Mio. EUR |
| 3.82 Mio. EUR |
| -52.44 Mio. EUR |
| -58.78 Mio. EUR |
| -0.2 EUR |
| 28.71 Mio. EUR |
| 16.09 Mio. EUR |
| -49.35 Mio. EUR |
| 0.81 |
| -4.08% |
| -10.63% |
| - |
| - |
| - |
| - |
| OCUGEN |
| 05.04.26 |
|